Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Transcept Pharmaceuticals

January 19, 2015

2014 sets post-crash venture record, but you ain’t seen nothing yet

March 25, 2013

Oblivion beckons for Remodulin as FDA again says no

Vantage logo
January 03, 2013

Pharma data news over the Christmas period

Vantage logo
December 06, 2012

Investors kick Chelsea after it trips on its Northera data again

Vantage logo
February 07, 2012

Merck’s new sleep drug has soporific effect on markets

Vantage logo
December 13, 2011

Alexza's failure to win broad backing for Adasuve could be last gasp

Vantage logo
November 24, 2011

Intermezzo approval not the end of Transcept thriller

Vantage logo
November 11, 2011

Nabi's demise and cash could attract IPO hopefuls

Vantage logo
September 19, 2011

Transcept and Vivus hoping to buck the trend with another approval chance

Vantage logo
September 02, 2011

PDUFA renewal plans include longer reviews and more meetings

Vantage logo
July 13, 2011

Intermezzo disappointment another rude awakening for Transcept

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
December 10, 2020

What the coming year might hold for biopharma

Vantage logo
December 11, 2020

Covid-19 vaccine developers remind the world that setbacks happen

Vantage logo
December 09, 2020

Astrazeneca’s vaccine looks increasingly like an also-ran

Vantage logo
November 09, 2020

Pfizer and Biontech snatch first Covid vaccine victory

Vantage logo
December 01, 2020

The promise and the perils of antigen testing

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.